- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02124213
A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)
Open Label Adaptive Design Study To Evaluate D1 Receptor Occupancy (ro) Following Single Dose Of Pf-06412562, Using Positron Emission Tomography (Pet) With Ligand [11c]sch23390 In Healthy Male Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Stockholm
-
Huddinge, Stockholm, Sweden, SE- 141 86
- Karolinska Trial Alliance (KTA) M62
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy Male Volunteers
Exclusion Criteria:
Evidence or history of clinically significant hepatic, renal, cardiovascular, endocrine, hematologic, gastrointestinal, pulmonary, neurologic, oncologic, psychiatric, or allergic disease Any condition possibly affecting drug absorption A positive urine drug screen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohor 1 - 30 mg
Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.
|
Subject will receive a single dose of 30 mg PF-06412562
|
Experimental: Cohort 2 ( adaptive dose, optional)
Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562.
The dose will be selected based on the results obtained for Cohort 1.
|
The dose will be selected based on the results obtained for Cohort 1.
This Cohort is optional.
The dose will be selected based on the results obtained for Cohort 1 and Cohort 2. This Cohort is optional. |
Experimental: Cohort 3 ( adaptive dose, optional)
Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562.
The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
|
The dose will be selected based on the results obtained for Cohort 1.
This Cohort is optional.
The dose will be selected based on the results obtained for Cohort 1 and Cohort 2. This Cohort is optional. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PF-06142562 plasma exposure and RO in the striatum
Time Frame: Day 1
|
Using Positron Emission Tomography and a radiotracer [11C]SCH23390, the PF-06142562 plasma exposure and RO in the striatum (average of caudate and putamen) will be measured in healthy male subjects.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time Frame: Day 1
|
Day 1
|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: Day 1
|
Day 1
|
Area under the plasma concentration-time profile from time zero to the last plasma measurement at 4 hours (AUC0-4)
Time Frame: Day 1
|
Day 1
|
Average plasma concentration over 4 hours (Cav,0-4)
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- B7441005
- 2013-004356-37 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on 30 mg PF-06412562
-
Yale UniversityNational Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaboratorsRecruitingEarly Course Schizophrenia Spectrum DisorderUnited States
-
PfizerTerminated
-
PfizerCompletedSchizophreniaUnited States
-
University of ZurichPfizerCompletedDecision MakingSwitzerland
-
PfizerCompletedParkinson's DiseaseUnited States
-
InvicroCompletedHealthy Male VolunteersUnited States
-
PfizerCompletedHepatic Impairment | Healthy ParticipantsUnited States
-
PfizerCompleted